• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

COVID-19 Clinical Trials: How AI-Based Chatbots Can Provide Pandemic-Level Execution

by Greg Kefer, Chief Marketing Officer, LifeLink 06/04/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
COVID-19 Clinical Trails: How AI-Based Chatbots Can Provide Pandemic-Level Execution
Greg Kefer, Chief Marketing Officer, LifeLink

More than 500 new COVID-19 related clinical trials have been registered as of the end of April. The race to find a COVID-19 vaccine is on and the public spotlight is on clinical trials. Strangely named drugs such as Hydroxychloroquine and Remdesivir have become household names and are featured and debated regularly on the 24-hour news channels. 

The pressure to find a cure is intense. The locked-down world does not want to hear that at best, we may find a vaccine sometime in 2021. What the world doesn’t realize is that 2021 would be nothing short of a miracle timeline for a new drug. What the experts know, the general public doesn’t want to hear: It usually takes several years to develop, test, prove, and manufacture a drug for safe use.  

Unfortunately, these are not normal times. The daily human and economic toll is upheaving the long practiced, structured process of drug development.  The FDA is fast-tracking approvals and processes in an effort to allow research and manufacturers to move quickly. While we have seen some progress, the process to test a new drug before it can be approved and manufactured at scale is typically a lengthy, manual process.


Challenges Administering Trials in the Face of Unprecedented Urgency

A typical therapy must undergo several multi-year phases to demonstrate efficacy and safety.  For each phase, a group of participants must be identified, recruited, qualified, and enrolled. In many cases, the enrollment process involves in-person screening, consent, lab tests, and evaluations. Sometimes these can be handled via phone. Most of the time, the recruitment and patient interactions are handled by clinical research coordinators at dozens of trial sites. It’s a complex process with many touchpoints. 

Sites struggle to identify patients, educate them about trial benefits, and enroll them in studies. In fact, 86% of clinical trials are delayed 1-6 months because they can’t meet their recruitment targets on time. 15-20% of trials never even enroll a single patient and are forced to close. 

The challenge doesn’t stop at enrollment. Once the trial is underway, patients are monitored and evaluated (often daily) for therapy efficacy, side effects, and impact on the quality of life. CRCs and patients alike burn out from the repetitive monotony of never-ending phone or in-person interviews. On average, 30% of patients drop out after enrollment, often because trial participation is overly burdensome or complicated. If patient numbers dwindle below the minimum thresholds for statistical viability, study timelines must be extended, delaying time to therapy.

Now consider the fact that a COVID-19 vaccine isn’t for a small subset of the population with a rare disease, but rather for everyone on the planet. So, while that might make finding volunteers easier, it will likely result in thousands of trials involving hundreds of thousands of patients across the globe. Coordinating, monitoring, and administering trial protocols for large patient populations, on accelerated timelines, will require millions of hours of effort. 


Speed and Scale through Patient Engagement Technology

Researchers know the stakes and will do everything they can to get the answers they need to find a cure. There are countless, incredible technologies at their disposal to help with the scientific discovery aspects of creating a new drug. But what about the heavy lifting of patient coordination, administration, and engagement for accelerated, large trials? How will we quickly recruit thousands of clinical research coordinators (CRCs) even as hospital systems and clinic resources are overwhelmed?

There appears to be an opportunity for more speed, efficiency and scale that is not being fully exploited in the clinical trials space. Many of the published abstracts and stories about trials tend to have one thing in common – lots of time-consuming, manual checks, conducted by human teams. Examples like this are common in the abstracts:

“The study, which is aiming to enroll 6,000 people, is also being conducted remotely, with participants receiving the drug in the mail and follow-up visits done via phone or video.”

“Study coordinators will be in contact directly with those accepted to schedule an initial enrollment visit. Once volunteers provide a blood sample, the study subjects will receive vials with unidentified, specific pills to take over the next eight weeks.”

Now, imagine if screening patients, scheduling clinic visits, reminding patients to adhere to trial protocols, and collecting patient-reported outcomes were delivered by a conversational digital assistant (a chatbot), instead of a CRC reading an IRB-approved script. What if we could automate 80% of the effort needed to manage a clinical trial protocol?

Augmenting CRC teams with smart chatbots that can handle complex outreach and data collection tasks with operational precision and consistency can deliver a 100x scale. Automating scripted, repetitive workflows to digital assistants allow CRCs and care teams to work at ‘top-of-license’, focusing on higher-value activities like high-risk patient follow up.

When it comes to creating a pandemic-level cure, maybe the time has come to think about scale and automation.  While conversational technology will never replace the brilliant human minds that are running these initiatives, its ability to automate interactions with large patient panels in a clinically precise manner can compress clinical trial timelines, reduce administrative overhead, and accelerate time to therapy.

Chatbots have proven to be effective ways to engage patients in healthcare, they can do the same in a clinical trial. It’s what patients prefer. It’s what the world needs right now.


About Greg Kefer, Chief Marketing Officer, LifeLink

Greg, as CMO at LifeLink, is responsible for strategy, branding, communications, and demand generation at the healthcare chatbot technology company. Large hospitals, pharmaceutical companies, and healthcare service providers use LifeLink bots to engage patient populations at scale, across a spectrum of workflows and scenarios. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, assistants, care teams, clinical research, Clinical Trails, Clinical Trial, Clinical Trials, FDA, patient engagement, risk, video

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |